Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial

Inclusion Criteria

• •Males or females ≥ 50 and ≤ 85 years at the time of signing the ICF;
• •Active macular choroidal neovascularization (MNV) secondary to nAMD in the study eye;
• •Sentinel (1st) subject for each dose cohort must have a BCVA ≤ 20/63 and ≥ 20/400 (≤63 and ≥ 19 ETDRS letters) in the study eye. Following the sentinel subject evaluation, the rest of the subjects in the dose cohort must have a BCVA between ≤ 20/40 and ≥ 20/400 (≤ 73 and ≥ 19 ETDRS letters) in the study eye.
• •Able to perform visual acuity and retinal function tests and able and willing to comply with study procedures for this clinical trial.